BAUSCH + LOMB CORP (BLCO) Stock News
NYSE:BLCO - New York Stock Exchange, Inc. - CA0717051076 - Common Stock - Currency: USD
BLCO Latest News, Press Relases and Analysis
Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises
The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.
Bausch and Lomb's dealmaking CEO Brent Saunders: No deal for company is imminent
Bausch and Lomb chairman and CEO Brent Saunders
Globus Medical (GMED) Q4 Earnings: What To Expect
Medical device company Globus Medical (NYSE:GMED) will be announcing earnings results tomorrow after the bell. Here’s what to expect.
Earnings To Watch: Integer Holdings (ITGR) Reports Q4 Results Tomorrow
Medical technology company Integer Holdings (NYSE:ITGR) will be announcing earnings results tomorrow before market hours. Here’s what you need to know.
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance
Mentions: BLCO.CA
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect
Eyecare company Bausch + Lomb (NYSE:BLCO) will be announcing earnings results tomorrow morning. Here’s what to expect.
Deal Dispatch: PharmChem Forgoes Banker To Run Sale, TGI Fridays Sells 19 Restaurants For $3.1 Million
Bausch + Lomb's efforts to sell have so far been unsuccessful. Meanwhile, KKR is aggressively pursuing a deal for Fuji Soft.
Bausch + Lomb Provides Update on Potential Sale
Mentions: BLCO.CA
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19
Mentions: BLCO.CA
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences
Mentions: BLCO.CA
Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union
Mentions: BLCO.CA
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge
Mentions: BLCO.CA
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Mentions: BLCO.CA
Bausch + Lomb Confirms It Is Exploring a Potential Sale
Bausch + Lomb said it authorized management and advisers to explore a potential sale of the eye health company after shares dropped over reports of faltering deal talks with a group of private equity firms.
Bausch + Lomb Responds to Rumors of a Potential Sale
Mentions: BLCO.CA
Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities
Mentions: BLCO.CA
Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
Mentions: BLCO.CA
Bausch + Lomb Announces Third-Quarter 2024 Results
Mentions: BLCO.CA
Banks, Private Credit Vie for $5 Billion Bausch + Lomb Financing
Banks and private credit firms are competing to provide at least $5 billion of debt financing to help fund a potential buyout of Bausch + Lomb, according to people with knowledge of the matter.
Why Bausch + Lomb Stock Soared by Over 7% on Monday
It was quite a busy and eventful day for the company.
Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens
Mentions: BLCO.CA
Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30
Mentions: BLCO.CA
Bausch + Lomb Launches Opal™ Digital Marketplace in the United States
Mentions: BLCO.CA